Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Keybanc Maintains Overweight on Synopsys, Raises Price Target to $455

Keybanc Maintains Overweight on Synopsys, Raises Price Target to $455

Keybanc analyst Jason Celino maintains Synopsys (NASDAQ:SNPS) with a Overweight and raises the price target from $445 to $455.

byBenzinga Newsdesk

August 18, 2022

1 minute read

Keybanc analyst Jason Celino maintains Synopsys (NASDAQ:SNPS) with a Overweight and raises the price target from $445 to $455.

Analyst Ratings

Analyst Ratings for JPMorgan Chase

By Benzinga Insights

June 15, 1:01 PM

JPMorgan Chase (NYSE:JPM) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

JPM

News

Introducing The Venmo Teen Account

By Benzinga Newsdesk

May 22, 8:15 AM

Parents and legal guardians can now open a Venmo Teen Debit Card and a Venmo account for teenagers 13 to 17 years old, so they can send, receive, and spend moneyOffers built-in parental controls and oversight

PYPL

Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

December 9, 2:48 PM

Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.

ACER

Gentex Q3 Earnings Miss Estimates

By Shivani Kumaresan

October 28, 12:22 PM

Gentex Corp (NASDAQ:GNTX) reported third-quarter FY22 sales growth of 24% year-on-year to $493.6 million, missing the analyst consensus estimate of $496.29…

GNTX

Keybanc Maintains Overweight on Synopsys, Raises Price Target to $455

Related Posts

Analyst Ratings for JPMorgan Chase

Introducing The Venmo Teen Account

Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday’s Mid-Day Session

Gentex Q3 Earnings Miss Estimates